Form 4: Zai Lab Director Michel Vounatsos Acquires Restricted Shares

Director Michel Vounatsos acquired 21,253 restricted shares of Zai Lab Ltd on June 18, 2024, which will vest on June 18, 2025, subject to continued service on the board.

Summary

• Michel Vounatsos, a director of Zai Lab Ltd, acquired 21,253 American Depositary Shares (ADS) on June 18, 2024.
• The shares are restricted and will vest fully on June 18, 2025, contingent upon Vounatsos' continued service as a board member.
• Each ADS represents ten ordinary shares of Zai Lab.
• Following the transaction, Vounatsos beneficially owns 39,585 ADSs.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the acquisition of restricted shares by a director typically indicates confidence in the company's future prospects. However, it's a routine transaction and doesn't necessarily signal a major shift in the company's outlook.

Positives

• The acquisition of restricted shares by a director signals confidence in the company's future.

Risks

• The vesting of the restricted shares is contingent upon continued service, which introduces a dependency on the director's ongoing involvement.

Future Outlook

The vesting of the shares on June 18, 2025, is contingent upon the director's continued service, aligning their interests with the company's long-term performance.

Industry Context

Acquisition of restricted stock is a common practice to align the interests of company directors with those of shareholders, incentivizing long-term value creation.

Comparison to Industry Standards

• Stock grants to directors are a standard practice in the biotech industry, often used to attract and retain talent.
• Companies like Amgen and Gilead Sciences also use stock grants as part of their director compensation packages.
• The vesting schedules and amounts vary based on company size, performance, and individual contributions.

Key Dates